Lower p66Shc promoter methylation in subjects with chronic renal failure.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 17 06 2021
accepted: 24 08 2021
entrez: 16 9 2021
pubmed: 17 9 2021
medline: 18 11 2021
Statut: epublish

Résumé

To determine the correlation between DNA methylation of p66Shc promoter and some markers of inflammatory and oxidative stress in chronic renal failure (CRF) patients compared with healthy subjects. An observational cross-sectional study was conducted in the nephrology department at Sidi Bouzid Regional Hospital (Tunisia). In total, 39 patients with CRF and 37 healthy subjects were included. Several biochemical parameters were measured. Furthermore, markers of the oxidative and inflammatory status (MDA, TAS, SOD, and CRP) were evaluated. The p66Shc methylation status was determined using the methylation-specific PCR. Our results showed that levels of blood glucose, urea, creatinine, uric acid, ChT, TG, albuminuria, CRP and MDA were significantly elevated in CRF patients compared to controls. Furthermore, p66Shc promoter region was highly demethylated in CRF patients compared to healthy controls (84% vs 4%). Our data showed a positive correlation between p66Shc hypomethylation and levels of MDA (r = 0.93; p<0, 05) and CRP (r = 0.89; P <0, 05), as well as a significant negative correlation between p66Shc hypomethylation, TAS (r = -0.76; P <0, 05) and SOD (r = -0.77; p<0, 05) levels. Similarly, there was a positive correlation between p66Shc hypomethylation and the disease stages. Importantly, multiple regression analysis showed that p66shc DNA hypomethylation remains strongly correlated with MDA, CRP and stages of CRF. This study indicates that the DNA hypomethylation of p66shc promoter was correlated with oxidative and inflammatory stress and the disease stages in CRF patients.

Identifiants

pubmed: 34529688
doi: 10.1371/journal.pone.0257176
pii: PONE-D-21-19910
pmc: PMC8445414
doi:

Substances chimiques

SHC1 protein, human 0
Src Homology 2 Domain-Containing, Transforming Protein 1 0
Malondialdehyde 4Y8F71G49Q

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0257176

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Acta Naturae. 2010 Oct;2(4):44-51
pubmed: 22649663
Sleep Breath. 2016 Mar;20(1):339-44
pubmed: 26271951
Circ Res. 2011 Sep 2;109(6):639-48
pubmed: 21778425
J Intern Med. 2007 May;261(5):488-99
pubmed: 17444888
Am J Physiol Renal Physiol. 2010 Nov;299(5):F1014-25
pubmed: 20739391
Int J Mol Sci. 2017 Feb 11;18(2):
pubmed: 28208659
J Cell Physiol. 2010 Feb;222(2):444-55
pubmed: 19918794
Epigenetics. 2016 Mar 3;11(3):227-36
pubmed: 26891033
Clin Psychopharmacol Neurosci. 2018 Feb 28;16(1):88-94
pubmed: 29397670
Sci Rep. 2016 Jul 05;6:29302
pubmed: 27377870
Arch Oral Biol. 2015 Dec;60(12):1784-8
pubmed: 26451646
Presse Med. 2009 Nov;38(11):1667-79
pubmed: 19303736
Annu Rev Pharmacol Toxicol. 1983;23:239-57
pubmed: 6307121
Antioxid Redox Signal. 2016 Jul 20;25(3):119-46
pubmed: 26906267
Circ Res. 2012 Jul 20;111(3):278-89
pubmed: 22693349
Chem Biol Interact. 2017 Dec 25;278:162-169
pubmed: 28987327
Kidney Int. 2011 Jan;79(1):23-32
pubmed: 20881938
J Mol Cell Cardiol. 2015 Dec;89(Pt B):122-35
pubmed: 25655936
Am J Physiol Renal Physiol. 2018 Feb 1;314(2):F143-F153
pubmed: 28978535
Biomed Res Int. 2014;2014:193095
pubmed: 24734227
Clin J Am Soc Nephrol. 2012 Dec;7(12):1938-46
pubmed: 23024164
J Exp Med. 2008 Sep 29;205(10):2409-17
pubmed: 18809715
BMC Ophthalmol. 2018 Feb 27;18(1):58
pubmed: 29482510
Methods Mol Biol. 2011;791:11-21
pubmed: 21913068
Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5217-22
pubmed: 17360381
Diabetes. 2011 Apr;60(4):1304-13
pubmed: 21357467
Nutrients. 2020 Mar 20;12(3):
pubmed: 32245085
Antioxid Redox Signal. 2014 Jan 1;20(1):74-101
pubmed: 23472618
Nat Genet. 2010 May;42(5):376-84
pubmed: 20383146
Antioxidants (Basel). 2020 Jun 10;9(6):
pubmed: 32532064
Am J Physiol Heart Circ Physiol. 2012 Jul 15;303(2):H189-96
pubmed: 22661506
Thromb Res. 2000 Sep 1;99(5):453-9
pubmed: 10973673
Epigenetics. 2021 Jan;16(1):92-105
pubmed: 32692944
Mediators Inflamm. 2014;2014:147040
pubmed: 25400332
Kidney Int. 2004 Mar;65(3):1009-16
pubmed: 14871421
Biochem Biophys Rep. 2019 Jan 11;17:169-176
pubmed: 30656220
Clin J Am Soc Nephrol. 2008 Sep;3(5):1569-72
pubmed: 18667739
Circulation. 2004 Nov 2;110(18):2889-95
pubmed: 15505103
Cardiovasc Res. 2011 Dec 1;92(3):466-75
pubmed: 21933910
FEBS J. 2011 May;278(10):1598-609
pubmed: 21395977
Acta Biochim Biophys Sin (Shanghai). 2019 Feb 1;51(2):197-203
pubmed: 30590376
J Ethnopharmacol. 2018 Feb 15;212:153-165
pubmed: 29032117
Atherosclerosis. 2015 Apr;239(2):393-400
pubmed: 25682038
Int J Cardiol. 2018 Oct 1;268:179-186
pubmed: 30047409
Biomed Pharmacother. 2018 Nov;107:834-840
pubmed: 30142545
Clin Chem Lab Med. 2007;45(12):1764-70
pubmed: 18067454
J Clin Endocrinol Metab. 2005 Feb;90(2):1130-6
pubmed: 15562031

Auteurs

Radhia Hamdi (R)

Faculty of Pharmacy, Research unit of clinical and molecular biology (UR17ES29), Department of biochemistry, University of Monastir, Monastir, Tunisia.
Laboratory of Biochemistry, Sidi Bouzid Regional Hospital, Sidi Bouzid, Tunisia.

Amana Saadallah-Kallel (A)

Laboratory of Molecular Biotechnology of Eukaryotes, Biotechnology Center, University of Sfax, Sfax, Tunisia.

Slima Ferchichi-Trimeche (S)

Faculty of Pharmacy, Research unit of clinical and molecular biology (UR17ES29), Department of biochemistry, University of Monastir, Monastir, Tunisia.
CHU Research Unit, Farhat Hached, Sousse, Tunisia.

Raja Mokdad-Gargouri (R)

Laboratory of Molecular Biotechnology of Eukaryotes, Biotechnology Center, University of Sfax, Sfax, Tunisia.

Abdelhedi Miled (A)

CHU Research Unit, Farhat Hached, Sousse, Tunisia.

Bachir Benarba (B)

Faculty of Nature and Life, Laboratory Research on Biological Systems and Geomatics, University of Mascara, Mascara, Algeria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH